Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery

Haematologica. 2007 Mar;92(3):366-73. doi: 10.3324/haematol.10913.

Abstract

Background and objectives: Since the impairment of platelet function may cause excess peri-operative bleeding, pre-operative discontinuation of aspirin and heparin bridging are common for cardiac surgery. We evaluated the impact of pre-operative administration of enoxaparin and unfractionated heparin (UFH) on coagulation parameters and peri-operative bleeding in patients undergoing elective coronary artery bypass grafting (CABG) surgery after discontinuation of aspirin.

Design and methods: Forty-three patients with three-vessel coronary artery disease undergoing elective CABG surgery discontinued aspirin and were randomized to receive either UFH 180 UI/Kg x 2/day s.c. or enoxaparin 100 UI/Kg x 2/day s.c. until 12 h before surgery (median pre-operative treatment 8 days, range 6-12 days). Surgery was performed as usual with UFH. Neither UFH nor any low molecular weight heparin was given in the immediate post-operative period. The effects of UFH and enoxaparin were monitored by the activated partial thromboplastin time (aPTT) and the Enox-test (sensitive to factor Xa inhibition) using a Rapidpoint Coagulation Analyzer. aPTT and factor Xa activity were also measured by standard methods. Peri-operative bleeding and the nadirs of hemoglobin concentration, hematocrit and platelet count were monitored post-operatively.

Results: Patients in the two groups were similar for number of bypasses, on-pump time, total surgery time, and time from the last heparin administration. Coagulation parameters increased significantly and similarly at 30 min and 6 h with both treatments, but returned within the normal range at 12 h. Hemoglobin, hematocrit and platelet counts significantly decreased to the same extent after CABG and re-normalized at the same time. Transfusional requirements of blood and plasma units were similar in the two groups.

Interpretation and conclusions: From the kinetics of coagulation parameters and the evaluation of bleeding, enoxaparin is a safe alternative to UFH as a bridging therapy to CABG after discontinuation of aspirin.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use
  • Blood Coagulation Tests
  • Blood Loss, Surgical / prevention & control
  • Blood Loss, Surgical / statistics & numerical data*
  • Coronary Artery Bypass*
  • Coronary Disease / surgery
  • Elective Surgical Procedures
  • Enoxaparin / administration & dosage
  • Enoxaparin / adverse effects*
  • Enoxaparin / therapeutic use
  • Factor Xa / analysis
  • Female
  • Hemoglobins / analysis
  • Heparin / administration & dosage
  • Heparin / adverse effects*
  • Heparin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Partial Thromboplastin Time
  • Platelet Count
  • Postoperative Complications / prevention & control
  • Postoperative Hemorrhage / chemically induced
  • Preanesthetic Medication / adverse effects*
  • Preoperative Care / adverse effects*
  • Sample Size
  • Thrombosis / prevention & control

Substances

  • Anticoagulants
  • Enoxaparin
  • Hemoglobins
  • Heparin
  • Factor Xa